Zydus Lifesciences Ltd Upgraded to Buy by MarketsMOJO on Strong Technical and Fundamental Grounds

Technical Trends Shift to Bullish Momentum

The primary catalyst for the upgrade lies in the technical analysis of Zydus Lifesciences’ stock price movements. The technical grade has improved from mildly bullish to bullish, signalling stronger market momentum. Key indicators reveal a mixed but overall positive picture: the Moving Average Convergence Divergence (MACD) is mildly bearish on a weekly basis but bullish monthly, while the Relative Strength Index (RSI) remains neutral with no clear signals on both weekly and monthly charts.

Bollinger Bands show bullish tendencies weekly and mildly bullish monthly, suggesting the stock is trading with upward volatility and potential for further gains. Daily moving averages confirm a bullish trend, supported by On-Balance Volume (OBV) readings that are bullish on both weekly and monthly timeframes, indicating strong buying pressure. Although the Dow Theory remains mildly bearish on weekly and monthly charts, the overall technical momentum has shifted favourably.

Price action supports this technical optimism: the stock closed at ₹1,161.00 on 22 September 2026, near its 52-week high of ₹1,205.65, and has outperformed the Sensex significantly over multiple periods. For instance, Zydus Lifesciences delivered a 26.93% year-to-date return compared to the Sensex’s negative 12.55%, and a 12.13% return over the last year versus the Sensex’s -9.29%. This outperformance underpins the bullish technical stance.

Valuation Remains Attractive Amidst Sector Peers

Zydus Lifesciences is classified as a mid-cap stock with a market capitalisation reflecting its solid position in the Pharmaceuticals & Biotechnology sector. The company’s valuation metrics support the upgrade, with an Enterprise Value to Capital Employed (EV/CE) ratio of 3.7, which is considered attractive relative to peers. This suggests the stock is trading at a fair price for the capital it employs to generate earnings.

Moreover, the company’s Price/Earnings to Growth (PEG) ratio stands at 4.6, indicating that while growth expectations are priced in, the valuation remains reasonable given the company’s consistent earnings growth. Over the past year, profits have increased by 4.2%, complementing the 12.13% stock return. This balance of valuation and growth prospects has contributed to the positive reassessment.

Financial Trend: Strong Long-Term Growth Despite Recent Setbacks

While the recent quarterly financial performance for Q1 FY26-27 showed a decline, with PAT falling by 35.0% to ₹953.07 crore and operating profit to interest coverage ratio dropping to 12.37 times, the company’s long-term financial trajectory remains robust. Net sales have grown at an annualised rate of 13.79%, and operating profit has expanded at 19.95% annually, underscoring healthy operational efficiency and revenue growth over time.

Zydus Lifesciences maintains a low average debt-to-equity ratio of 0.05 times, highlighting its conservative capital structure and limited financial risk. Return on Equity (ROE) averages 17.49%, reflecting strong profitability per unit of shareholder funds, while Return on Capital Employed (ROCE) is an attractive 21.8%, albeit with a slight dip to 19.13% in the half-year period. These metrics reinforce the company’s capacity to generate value sustainably.

Quality Assessment: High Ratings and Consistent Outperformance

The company’s quality grade has been a key factor in the upgrade. Zydus Lifesciences is ranked among the top 1% of all 4,000 stocks rated by MarketsMojo, a testament to its strong fundamentals and market standing. It has consistently outperformed the BSE500 index over the last three years, delivering cumulative returns of 94.93% compared to the index’s 12.91% over the same period.

Promoters remain the majority shareholders, providing stability and alignment with shareholder interests. The company’s consistent returns and strong financial discipline have earned it a Mojo Score of 71.0 and a Mojo Grade upgrade from Hold to Buy, reflecting confidence in its future prospects despite short-term earnings volatility.

Balancing Risks with Long-Term Potential

Investors should note the recent negative quarterly results, which represent a short-term challenge. The 35.0% decline in PAT and the lowest operating profit to interest coverage ratio in recent quarters highlight some operational pressures. Additionally, the half-year ROCE at 19.13% is the lowest recorded in recent periods, signalling some margin compression.

However, these setbacks are tempered by the company’s strong balance sheet, low leverage, and consistent long-term growth trends. The stock’s technical indicators suggest renewed buying interest, and its valuation remains reasonable compared to sector peers. This combination of factors justifies the upgrade to a Buy rating, signalling confidence in the company’s ability to navigate near-term challenges and deliver shareholder value over time.

Conclusion: A Buy Rating Reflecting Strength Across Multiple Dimensions

Zydus Lifesciences Ltd’s upgrade from Hold to Buy by MarketsMojo on 22 September 2026 is underpinned by a comprehensive improvement in technical signals, attractive valuation metrics, solid long-term financial trends, and high-quality fundamentals. Despite recent quarterly earnings weakness, the company’s low debt, strong profitability, and consistent market outperformance provide a compelling investment case.

With a Mojo Score of 71.0 and a position among the top 1% of rated stocks, Zydus Lifesciences stands out as a mid-cap pharmaceutical stock with promising upside potential. Investors seeking exposure to the Pharmaceuticals & Biotechnology sector may find this upgrade a timely signal to consider adding the stock to their portfolios, balancing short-term risks with long-term growth prospects.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →